A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting

Sarah E. Hugo,1,2 Lourdes Cruz-Garcia,1,2 Santhosh Karanth,1,2 Ryan M. Anderson,3,5 Didier Y.R. Stainier,3 and Amnon Schlegel1,2,4,6

1University of Utah Molecular Medicine (U2M2) Program, 2Department of Internal Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Utah, Salt Lake City, Utah 84112, USA; 3Department of Biochemistry and Biophysics, Liver Center, Diabetes Center, Cardiovascular Research Institute, University of California at San Francisco, San Francisco, California 94158, USA; 4Department of Biochemistry, School of Medicine, University of Utah, Salt Lake City, Utah 84112, USA

To find new genes that influence liver lipid mass, we performed a genetic screen for zebrafish mutants with hepatic steatosis, a pathological accumulation of fat. The red moon (rmn) mutant develops hepatic steatosis as maternally deposited yolk is depleted. Conversely, hepatic steatosis is suppressed in rmn mutants by adequate nutrition. Adult rmn mutants show increased liver neutral lipids and induction of hepatic lipid biosynthetic genes when fasted. Positional cloning of the rmn locus reveals a loss-of-function mutation in slc16a6a (solute carrier family 16a, member 6a), a gene that we show encodes a transporter of the major ketone body β-hydroxybutyrate. Restoring wild-type zebrafish slc16a6a expression or introducing human SLC16A6 in rmn mutant livers rescues the mutant phenotype. Radiotracer analysis confirms that loss of Slc16a6a function causes diversion of liver-trapped ketogenic precursors into triacylglycerol. Underscoring the importance of Slc16a6a to normal fasting physiology, previously fed rmn mutants are more sensitive to death by starvation than are wild-type larvae. Our unbiased, forward genetic approach has found a heretofore unrecognized critical step in fasting energy metabolism: hepatic ketone body transport. Since β-hydroxybutyrate is both a major fuel and a signaling molecule in fasting, the discovery of this transporter provides a new direction for modulating circulating levels of ketone bodies in metabolic diseases.

[Keywords: hepatic steatosis; ketone body; lipid metabolism; starvation; zebrafish]

Supplemental material is available for this article.

Received October 13, 2011; revised version accepted December 27, 2011.

Hepatic steatosis is present in a large fraction of obese people (Clark 2006). Nonalcoholic fatty liver disease (NAFLD) encompasses hepatic steatosis and several pathological states that follow it: inflammation (steatohepatitis), fibrosis (cirrhosis), and cancer (hepatocellular carcinoma) (Liou and Kowdley 2006). There are limited therapeutic options for permanently ameliorating hepatic steatosis (Sanyal et al. 2010), and there are no methods for reversing hepatic fibrosis or preventing hepatocellular carcinoma due to NAFLD (Nugent and Younossi 2007). The first step of NAFLD is the inappropriate accumulation of triacylglycerol in hepatocytes (Browning and Horton 2004). This accumulation may be due to excessive de novo hepatic lipid production; decreased hepatic secretion of very-low-density lipoprotein (VLDL) particles; diminished β-oxidation of fatty acids in the liver; exaggerated uptake of fatty acids from the circulation; more subtle defects in regulating energy homeostasis, including insulin resistance or CNS nutrient sensing; or a combination of these factors (Hooper et al. 2011). Since each of these processes could be exploited therapeutically, understanding their regulation is paramount. Identifying and characterizing novel genes that modulate hepatic lipid mass are priorities (Cohen et al. 2011).

Master transcription factors, metabolic regulators, and multiple enzymes that control lipid homeostasis are present in zebrafish (Babin and Vernier 1989; Ihae et al. 2002; Schlombs et al. 2003). This conservation of function and the absence of fasting steatosis in larvae that have never been fed (Schlegel and Stainier 2006) allowed us to screen for mutations causing increased hepatic lipid mass. Performing the screen in animals carrying three transgenes that encode fluorescent protein labels of the Islet of Langerhans β cells, the liver hepatocytes, and the pancreatic...
Results

Isolation and initial characterization of red moon (rmn), a zebrafish mutant with hepatic steatosis

The rmn mutant showed hepatic steatosis just as maternally supplied yolk lipids were nearing exhaustion on 5 dpf (Fig. 1A). Aside from the surfactant-lined swim bladder, only the rmn mutant liver showed strong Oil Red O (ORO) staining on 6 and 7 dpf. The accumulation of neutral lipids in rmn mutant livers was confirmed with both whole-mount and confocal microscopy of animals stained with the fluorescent neutral lipid dye 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene [BODIPY 493/503] (Fig. 1B,C). Numerous cytoplasmic lipid droplets in otherwise normal hepatocytes were observed in rmn mutants examined with transmission electron microscopy (Fig. 1D). Normal macronutrient recycling was appreciated in rmn livers viewed at higher magnification (Fig. 1D). Similarly, histological analysis demonstrated no evidence of inflammatory cell infiltration or deposition of excessive extracellular matrix proteins (Supplemental Fig. S1A,B). Taken together, the histological and ultrastructural characterization indicated that our stringent screening criteria were met: The fulminant hepatic degeneration seen in other zebrafish mutants with hepatic steatosis did not occur in rmn mutants.

The lack of secondary phenotypes in rmn mutants enabled us to assess whether the steatosis phenotype would be modulated by prolonged fasting. Hepatic steatosis in rmn mutants persisted in the never-fed state to 12 dpf in the absence of other, overt morphological defects (Supplemental Fig. S1C). This persistence of hepatic steatosis prompted us to quantify the major neutral lipid species in whole-larval extracts over the course of a prolonged fast. There were increased levels of triacylglycerol, β-hydroxybutyrate, and free fatty acids in whole-larval extracts 5 dpf (Fig. 2A). The lipid compositions of wild-type and rmn mutant larvae changed over the course of the fast. Cholesterol was the most abundant neutral lipid in whole-larval extracts and was more abundant in rmn mutant extracts on 7 and 8 dpf. Similar to β-hydroxybutyrate and free fatty acids, the triacylglycerol was also higher in 5- and 6-dpf rmn mutant extracts. Cholesteryl esters were more abundant in rmn mutants between 7 and 10 dpf. Thereafter, the whole-larval levels of all three neutral lipids were not different. In summary, never-fed rmn mutants showed persisting hepatic steatosis marked by accumulation of different neutral lipid species until death by 13 dpf.

Since rmn mutant larvae showed no obvious morphological phenotypes, it was possible that the mutation was not lethal. We raised an in-cross of heterozygous carriers under normal feeding conditions and observed that the rmn mutant was viable [recovered in the anticipated Mendelian ratio of a fully penetrant and fully expressive recessive mutation] and fertile. Thus, we were able to assess the changes in hepatic neutral lipid composition by subjecting wild-type and rmn mutant adult animals to a
2-wk fast and analyzing their dissected livers. Recapitulating the larval phenotype, fasted rmn mutants showed increased levels of triacylglycerol, cholesterol, and cholesteryl esters [Fig. 2B]. Importantly, this experimental approach led to equal protein mass loss in fasted wild-type and rmn mutant livers [Fig. 2C]. Validating our experimental design, we observed that wild-type and rmn mutant adults were hypoglycemic and had lower blood triacylglycerol concentrations when fasted [Fig. 3D]. The adult rmn livers showed modest microvesicular steatosis without evidence of inflammation [Supplemental Fig. S2]. Intrahepatic β-hydroxybutyrate was slightly lower in fasting rmn livers [Supplemental Fig. S3A]. The serum β-hydroxybutyrate did not rise during the fasting period, even in wild-type animals [Supplemental Fig. S3B].
Figure 3. Positional cloning of the \textit{rmn} locus. (A) The \textit{rmn} locus was narrowed to a 100-kb critical interval on chromosome 12. Genetic distance of markers is reported on the radiation hybrid map in centiRays (cR) and on the MGH meiotic map in centiMorgans (cM) above individual bacterial artificial chromosome and fosmid clones used to span this region of the genome. The recombination events [reported as recombinants/meioses] at the labeled polymorphic markers [poly-CA or “CA repeat”) are shown below individual clones. Clone acronym definitions and the names of the clones between \textit{zK29B5} and \textit{zC29A20} are in the Supplemental Material. (B) Fine mapping narrowed the critical interval to the space between two CA repeats within introns of \textit{slc16a6a} and \textit{calcoco2} on the clone \textit{zK106L8} (white region flanked by gray and red portions of the chromosome). Coding exons are filled red boxes. The 5' and 3' untranslated regions (UTRs) are unfilled boxes. (C) Sanger traces of \textit{slc16a6a} cDNAs prepared with primers in the 5' and 3' UTRs indicating that exon 2 is skipped in \textit{rmn} mutants. The position of leucine codon 86 and methionine codon 97 are shown. (D) Cartoons of \textit{slc16a6a} cDNAs prepared as in C. (E) Sanger traces of genomic DNA spanning exon 2 of \textit{slc16a6a} reveal retrotransposon sequences in \textit{rmn} mutants. An in-frame stop codon is shown. (F) Cartoon of the insertion mutation destroying exon 2 of \textit{slc16a6a}. (G, left) The sequenced products shown in \textit{E} differ in size: Amplification of exon 2 and flanking intronic sequences of \textit{slc16a6a} from homozygous wild-type animals (+/+), heterozygous \textit{rmn} carriers (+/rmn), and homozygous \textit{rmn} mutant animals (rmn/rmn) reveals a 450-bp increase in the \textit{rmn} allele product. (Left panel) Heterozygous carriers proved difficult to score using this primer pair because the mutant allele amplified less robustly in the presence of the wild-type allele (primers A and B). (Right panel) Thus, we resorted to a three-primer strategy to amplify either the sequences deleted by the insertion or a small portion of the insertion. The latter approach led to confident scoring of heterozygous carriers. The molecular mass standards are shown in kilobase pairs.
The **rmn** mutation disrupts an orphan monocarboxylate transporter (MCT) gene

Positional cloning methods were used to isolate the gene disrupted by the **rmn** mutation [Fig. 3A,B]. Of the genes within the critical interval on chromosome 12, **slc16a6a** (solute carrier family 16a, member 6a) was a strong candidate because it encodes an orphan MCT that may be required in the transport of nutrients as animals transition from fed to fasted states [Price et al. 1998]. We cloned and sequenced mature **slc16a6a** cDNAs from adult liver and observed aberrant mRNA maturation with skipping of the initiator ATG codon-containing exon 2 in **rmn** mutants [Fig. 3C,D]. In **rmn** mutants, the 3′ 169 base pairs [bp] of exon 2 and the first 67 bp of intron 2 in the **slc16a6a** gene were replaced by a 404-bp sequence that is most similar to the Dnqar04 retrotransposon [Fig. 3E–G; Supplemental Fig. S4; Goodwin and Poulter 2004]. Thus, the **rmn** mutation was not induced by N-ethyl-N-nitrosourea. Rather, it was carried in some of the mutagenized animals we used for the screen [Anderson et al. 2009]. The **rmn** mutation was found in other strains [Supplemental Material], but not in the one we used in our previous studies [Schlegel and Stainier 2006].

In contrast to the nearly ubiquitous expression of Slc16a1 (MCT1) and Slc16a7 (MCT2), the expression of Slc16a6 is limited to liver, pancreas, skin, vas deferens, and testis of adult rats [Bonen et al. 2006]. The expression pattern of Slc16a6 during development is not known. The zebrafish **slc16a6a** transcript was not maternally deposited, but was detected throughout the embryonic and early larval period [Fig. 4A]. Whole-mount in situ hybridization revealed expression of **slc16a6a** in the head and pronephros early in development and increased expression in the liver, proximal intestine, and swim bladder by 5 dpf [Fig. 4B].

Slc16a6 family proteins have 12 transmembrane domains [Price et al. 1998]. By skipping exon 2, the mature **rmn** mutant transcript lacks the initiator codon, however, the mRNA we isolated may still encode an N-terminally deleted Slc16a6a protein beginning with methionine codon 97 [Figs. 3D,E, 4C], although a Kozak sequence does not precede this codon. Likewise, leucine codon 86 (CUG) could serve as a cryptic site of alternative translation initiation. Antibodies raised against the extreme C terminus of Slc16a6a protein allowed us to unequivocally exclude these possibilities [Supplemental Fig. S5]. Only wild-type Slc16a6a was detected by immunoblotting of proteins from dissected adult livers [Fig. 4D,E]. The **rmn** mutation inactivates the **slc16a6a** gene.

**Slc16a6a** is a ketone body transporter required in the liver during fasting

The activity of Slc16a6 has not been functionally characterized in any organism, yet it is very likely that zebrafish Slc16a6a is an active MCT because it shows conservation of catalytic residues initially identified in rat Slc16a1 [Supplemental Fig S3]. We expressed Slc16a6a heterologously in *Xenopus* oocytes and assessed whether the encoded protein can transport monocarboxylic acids, focusing on the most widely reported Slc16a family substrate (lactate) and two plausible substrates whose abundance increases in the fasting state: the major ketone body β-hydroxybutyrate, and the branched-chain keto acid isovalerate, which is liberated from leucine catabolism and serves as a ketogenic precursor. Inward currents were generated in Slc16a6a-expressing oocytes perfused with β-hydroxybutyrate, but not with isovalerate or lactate [Fig. 4F]. The current-to-voltage relationship indicates that, like all other previously studied Slc16a family members, Slc16a6a is not voltage-dependent [Fig. 4G]. Thus, of the plausible substrates examined, Slc16a6a appears to be a selective β-hydroxybutyrate transporter. We were unable to detect currents in **rmn** mutant **slc16a6a**-expressing oocytes [data not shown].

Since the liver is the major site of ketone body production in vertebrates [Phillips and Hird 1977], we...
Figure 5. (A) A model of the role of Slc16a6a in hepatic ketone body metabolism. Dietary and stored reduced carbon atoms in the form of fatty acids (intestine and adipose, respectively) can be delivered to the liver, where, after partial β-oxidation, they can be repackaged as ketone bodies for feeding the peripheral organs during fasting. Triacylglycerol can also be packaged into VLDL particles (liver) or chylomicrons (intestine) for delivery to the periphery. The intestine and skeletal muscle also provide ketogenic amino acids, the most abundant of which is leucine. In birds, reptiles, and mammals, the rate-limiting enzyme of ketogenesis is mitochondrial HMG-CoA synthase 2 (gray reactions), which arose in birds through gene duplication of the cytosolic HMG-CoA synthase 1 gene (Boukaftane et al. 1994). Amphibians, fish, and other lower vertebrates have only the cytosolic, cholesterol-synthetic HMG-CoA synthase 1 and rely on increased flux through deamination and oxidation of leucine (which also occurs in higher vertebrates) to make mitochondrial HMG-CoA for ketogenesis (Phillips and Hird 1977; Leblanc and Ballantyne 2000). Slc16a6a is a β-hydroxybutyrate-transporting MCT that is expressed in the liver. In rnm mutants, this transporter is inactivated, and the carbon atoms that would otherwise be secreted as fuel during fasting are diverted back to de novo lipogenesis and storage in lipid droplets. The peripheral ketone body transporters are not known (‘?’), but Slc16a1, Slc16a7, and Slc16a3 are expressed in brain endothelial cells, neurons, and astrocytes, respectively (Pierre and Pellerin 2005). In zebrafish, there is evidence that Slc5a family members are expressed in muscle and can transport sodium hydroxybutyrate [Plata et al. 2007]. (CoA) Coenzyme A; (Cpt1) Carnitine palmitoyl transferase 1; (Bckdh) Branched chain ketoacid dehydrogenase; (Chyl) chylomicron particle; (FAD) flavine adenine dinucleotide; (FADH2) reduced FAD; (NAD+) nicotinamide adenine dinucleotide; (NADH) reduced NADH; (VLDL) very low-density lipoprotein particle. (B) Larvae were incubated with L-[14C(U)]-leucine, and then lipids were analyzed as described in the Materials and Methods to calculate the 14C incorporation ratio. Values greater than unity reflect increased relative incorporation of ketogenic precursor carbon atoms into neutral lipids in rnm mutants.

| Cholesterol | Cholesteryl esters | Free Fatty Acids | Triacylglycerol |
|-------------|-------------------|-----------------|----------------|
| 0.83 ± 0.04 | 1.0 ± 0.1         | 1.3 ± 0.1       | 18 ± 6         |
hypothesize that the *rmn* mutation renders hepatocytes incapable of secreting ketone bodies [Fig. 5A]. We tested this model by incubating wild-type and *rmn* mutant larvae in L-[1-14C(U)]-leucine, a precursor of ketone bodies, and assessed for tracer incorporation into neutral lipids. A striking increase in relative incorporation of tracer into triacylglycerol, a modest increase into free fatty acids, and no increases into cholesterol and cholesteryl esters were seen in extracts of *rmn* mutants [Fig. 5B]. This finding confirms our hypothesis that loss of hepatic ketone body transport via Slc16a6a causes diversion of carbon atoms into neutral storage lipids. This finding also suggests that the lack of increased serum ketone bodies in fasting wild-type animals may reflect very rapid clearance from the serum.

To formally assess whether Slc16a6a expression is required in the liver, we restored wild-type *slc16a6a* expression in *rmn* mutants using transgenic tools that allowed both broad and liver-specific transgene activation. The *rmn* phenotype can be rescued by transgenic expression of wild-type *slc16a6a* exclusively in the liver (Fig. 6A). This result indicates that while this MCT is broadly expressed [Fig. 4B], its major site of action in regulating hepatic lipid mass during fasting is the liver. We also found that forced expression of the human ortholog SLC16A6 in *rmn* mutant hepatocytes could rescue the *rmn* phenotype, underscoring that this evolutionarily conserved gene appears to function similarly in higher vertebrates.

Consistent with our hypothesis that the *rmn* mutation causes diversion of carbon atoms from ketone bodies to neutral lipids, we found changes in the abundance of select transcripts encoding enzymes and transcription factors involved in lipid and ketone body metabolism in adult livers under fed and fasted states [Table 1]. In particular, there was induction of numerous Ppara targets, as expected in fasted animals [cpt1a [carnitine palmitoyl transferase 1a] and the messages encoding proteins involved in β-oxidation]. Interestingly, the *ppara* transcript was not altered, and we found that treatment with four different Ppara agonists did not rescue the *rmn* mutant phenotype, suggesting that this pathway is already maximally induced in *rmn* mutants [Supplemental Table S1]. In addition, fasted adult *rmn* mutant livers had increased abundance of transcripts encoding “adipogenic” transcription factors [srebf2 and cebpα], cholesterol biosynthetic enzymes, and enzymes of triacylglycerol synthesis. Taken together, this gene expression profile of adult livers suggests that disrupting hepatic ketone transport induces further expression of ketogeneic and branched-chain amino acid catabolic pathways. Also induced in an attempt to store carbon atoms that cannot be secreted are cholesterol biosynthetic and triacylglycerol biosynthetic genes. Likewise, fatty acyl oxidative pathways are up-regulated when ketone body transport is impaired.

As a final demonstration of the requirement of Slc16a6a in fasting physiology, we examined the consequences of feeding on the *rmn* phenotype. Gratifyingly, *rmn* mutants were not steatotic when fed from 5 to 12 dpf [Fig. 6B], however, withdrawal of food from *rmn* mutants, but not from wild-type animals, led to hepatic steatosis.
Liver ketone body transporter

Table 1. Quantitative RT–PCR gene expression profiling

| Gene                          | Protein                                      | Wild type Fasted | Fed | rmm mutant Fasted | Fed |
|-------------------------------|----------------------------------------------|------------------|-----|-------------------|-----|
| **Transcription factors regulating lipid metabolism** |                               |                  |     |                    |     |
| cebpa                         | CCAAT/enhancer-binding protein α             | 1.0 ± 0.01       | 1.8 ± 0.01 * | 2.6 ± 0.03 a      | 7.2 ± 0.03 b |
| pparab                        | Peroxisome proliferator-activated receptor α b | 1.0 ± 0.02       | 0.8 ± 0.02  | 0.9 ± 0.02        | 1.0 ± 0.03 |
| pparγ                         | Peroxisome proliferator-activated receptor γ | 1.0 ± 0.004      | 1.0 ± 0.007 | 1.1 ± 0.01        | 2.7 ± 0.02 * |
| nr1b3                         | Liver X receptor α                           | 1.0 ± 0.05       | 0.7 ± 0.01  | 0.8 ± 0.01        | 0.8 ± 0.01 |
| srebfl                        | Sterol regulatory element-binding transcription factor 1 | 1.0 ± 0.03 | 1.5 ± 0.05  | 1.2 ± 0.04        | 0.9 ± 0.03  |
| srebfl2                       | Sterol regulatory element-binding transcription factor 2 | 1.0 ± 0.1 | 3.0 ± 0.1 a | 2.1 ± 0.01 a      | 6.6 ± 0.4 a,b |
| mlxip                         | MLX-interacting protein [Chrebp]              | 1.0 ± 0.03       | 1.3 ± 0.03  | 1.7 ± 0.05        | 0.6 ± 0.03  |
| **Cholesterol synthesis**     |                               |                  |     |                    |     |
| hmgcra                        | 3-Hydroxy-3-methylglutaryl-coenzyme A reductase a | 1.0 ± 0.03       | 25.3 ± 1.3 a | 63 ± 1           | 3050 ± 30 b |
| hmgcsc                        | 3-Hydroxy-3-methylglutaryl-coenzyme A synthase 1 | 1.0 ± 0.01 | 41.3 ± 0.6 a | 5.9 ± 0.1 a      | 437 ± 6 b |
| hmgcl                         | 3-Hydroxy-3-methylglutaryl-coenzyme A lyase   | 1.0 ± 0.06       | 1.0 ± 0.06  | 1.7 ± 0.14 b     | 1.0 ± 0.06  |
| bcat2                         | Branched-chain ketoacid and ketone body metabolism |            |     |                    |     |
| bcket                         | Branched-chain aminotransferase, mitochondrial | 1.0 ± 0.02 | 4.14 ± 0.06 a | 8.1 ± 0.14 b    | 2.27 ± 0.03 a |
| bcdhbl                        | Branched-chain ketoacid dehydrogenase subunit b, like b | 1.0 ± 0.02 | 1.92 ± 0.03 a | 2.84 ± 0.04 b  | 1.34 ± 0.02 |
| bcdh1                         | 3-Hydroxybutyrate dehydrogenase, mitochondrial | 1.0 ± 0.06 | 1.0 ± 0.06  | 2.5 ± 0.14 b     | 0.5 ± 0.03  |
| oxct1b                        | 3-Oxoadic coenzyme A transferase 1b (liver-specific) | 1.0 ± 0.02 | 4.4 ± 0.1 a  | 8.5 ± 0.2 b      | 10.6 ± 0.4  |
| **De novo fatty acid and triacylglycerol synthesis and VLDL secretion** |                               |                  |     |                    |     |
| acc1                          | Acetyl-coenzyme A carboxylase 1              | 1.0 ± 0.07 | 51.9 ± 1.3 a | 0.7 ± 0.01      | 16.8 ± 0.2 a |
| fasn                          | Fatty acid synthase                          | 1.0 ± 0.05 | 70.5 ± 1.0 a | 1.2 ± 0.04      | 28.0 ± 0.4 a |
| scd                           | Steroyl-CoA desaturase [Δ-9-desaturase]       | 1.0 ± 0.02 | 8,520 ± 90 a | 58 ± 1 a        | 5080 ± 30 a |
| elovl5                        | Elongation of long chain fatty acids family member 5 | 1.0 ± 1.04 | 1.0 ± 0.23  | 0.3 ± 0.04 b     | 0.3 ± 0.03 b |
| fads2                         | Fatty acid desaturase 2 [Δ-5- and Δ-6-desaturase] | 1.0 ± 1.01 | 1.58 ± 0.01 | 0.4 ± 0.002     | 0.7 ± 0.004 |
| agpat4                        | 1-Acylglycerol-3-phosphate O-acyltransferase 4 | 1.0 ± 0.02 | 5.0 ± 0.1 a | 16.8 ± 0.4 b     | 9.9 ± 0.3 a,b |
| ppp2ab                        | Phosphatidic acid phosphatase 2a b           | 1.0 ± 0.03 | 2.8 ± 0.1   | 1.2 ± 0.03       | 0.7 ± 0.02  |
| dgot2                         | Diacylglycerol O-acyltransferase 2           | 1.0 ± 1.0        | 0.9 ± 0.1  | 14.9 ± 1.0 a     | 22.6 ± 2.3 a,b |
| mtp                           | Microsomal triglyceride transfer protein     | 1.0 ± 0.17 | 2.2 ± 0.4 a | 1.7 ± 0.3 a      | 3.4 ± 0.6 a |
| **Fatty acid oxidation**      |                               |                  |     |                    |     |
| cpl1a                         | Carnitine O-palmitoyltransferase 1 (liver isofrom) | 1.0 ± 0.03 | 1.3 ± 0.04 a | 1.4 ± 0.04 a    | 1.2 ± 0.04 a |
| acad1                         | Acyl-coenzyme A dehydrogenase, long chain    | 1.0 ± 0.03 | 5.1 ± 0.1 a | 3.2 ± 0.04 a    | 3.8 ± 0.04 a |
| acadm                         | Acyl-coenzyme A dehydrogenase, C-4 to C-12, straight chain | 1.0 ± 0.04 | 3.27 ± 0.04 a | 2.7 ± 0.04 a    | 2.3 ± 0.2 a |
| ehhad1                        | Enoyl-CoA, hydratase/3-hydroxyacyl CoA        | 1.0 ± 0.03 | 2.6 ± 0.08 a | 1.6 ± 0.05 a    | 2.3 ± 0.08 a |
| mt-nl1                        | NADH dehydrogenase 1, mitochondrial           | 1.0 ± 0.1        | 2.1 ± 0.1 a | 2.6 ± 0.03 a    | 2.0 ± 0.05 a |
| mt-co1                        | Cytochrome c oxidase 1, mitochondrial         | 1.0 ± 0.02 | 1.3 ± 0.01 a | 1.3 ± 0.02 a     | 1.4 ± 0.01 |
| mt-atp6                       | ATP synthase 6, mitochondrial                 | 1.0 ± 0.1        | 0.9 ± 0.03 | 0.8 ± 0.02       | 1.2 ± 0.03 |
| Scl16a6 paralogs              |                               |                  |     |                    |     |
| scl16a6a                      | Solute carrier family 16a, member 6a         | 1.0 ± 0.02 | 0.8 ± 0.02  | 1.2 ± 0.02       | 0.1 ± 0.002 |
| scl16a6b                      | Solute carrier family 16a, member 6b         | 1.0 ± 0.02 | 2.0 ± 0.04  | 2.6 ± 0.05       | 0.4 ± 0.01 b,a |

*aP < 0.01 versus wild type fasted.

*bP < 0.01 versus wild type fed.

[Fig. 6C,D]. To assess whether the development of steatosis in previously fed animals affected survival, wild-type and rmm mutant larvae were fed from 5 to 12 dpf and then scored for death after food was withdrawn. Again, as expected, wild-type animals survived longer than rmm mutant animals [Fig. 6E]. Thus, rmm mutant larvae develop hepatic steatosis under nutrient-deficient states and are rendered sensitive to starvation.

**Discussion**

In diverse metazoan species from flies [Gutierrez et al. 2007] to humans [Gibbons et al. 2000], fasting causes mobilization of energy substrates from the peripheral organs in the form of fatty acids from adipose and amino acids from muscle. Upon return to the liver, these metabolites are partially oxidized into ketone bodies, a fuel source that can be used by the brain. These molecules and the glucose liberated from hepatic glycogenolysis and gluconeogenesis are used as fuel in peripheral organs during fasting [Cahill 2006]. The availability of ketone bodies for use by organs other than the liver reflects the lower hepatic abundance of 3-oxoadiic coenzyme A (CoA) transferase 1, the enzyme required to break down ketone bodies [Laffel 1999].

In inbred strains of mice, the influx of fatty acids from adipose tissue during fasting leads to their re-esterification and temporary storage in the liver. The extent of this steatosis varies based on genetic background and reflects differences in muscle fat oxidation and the degree of

**GENES & DEVELOPMENT**  289
adipose lipolysis [Lin et al. 2005; Guan et al. 2009]. Furthermore, there is an inverse association between hepatic lipid levels and serum ketone body concentrations in fasted mice [Lin et al. 2005]. Normal humans subjected to fasting show an increase in hepatic lipid content in response to a 36-h fast, but there is variation in the extent of lipid accumulation [Moller et al. 2008].

Here we described the use of a genetic screen to isolate novel regulators of lipid metabolism. Our approach led to the identification of a nutritionally suppressible hepatic steatosis mutant, *rmn*. In contrast to previously reported, lethal mutants, the steatosis seen in *rmn* mutants is neither preceded nor followed by the development of degenerative changes in hepatocyte architecture or fulminant inflammation. The *rmn* mutation causes a complete loss of Slc16a6a expression, as revealed by the absence of mutant protein expression. The mutated gene encodes a MCT that transports β-hydroxybutyrate Slc16a6a. Mutation of this ketone body transporter triggers accumulation of neutral lipids in fasted livers and renders animals sensitive to starvation. The *rmn* mutant phenotype can be rescued by forced expression of wild-type *slc16a6a* exclusively in the liver. Expression of the human ortholog *SLC16A6* in the liver also rescues the mutant phenotype. Taken together, our loss-of-function genetic data, transgenic rescue observations, transporter characterization, radiotracer study, and nutritional manipulations indicate that Slc16a6a is a hepatic ketone body transporter required during fasting (Fig. 5).

Placed in a broader context, the *rmn* mutant phenotype is reminiscent of that seen when Ppara function is lost. In *Ppara*−/− mice, there is fasting hepatic steatosis and hypoketonaemia [Kersten et al. 1999; Hashimoto et al. 2000]. Liver-restricted inactivation of *Tbll*, which encodes Transducin β-like 1, a heterodimerization partner of Ppara, causes phenotypes similar to *Ppara* inactivation [Kulozik et al. 2011]. Several Ppara targets are induced in *rmn* mutants beyond the anticipated increases seen in fasted wild-type animals (Table 1). This induction is probably maximal because treatment with synthetic Ppara ligands did not rescue the *rmn* mutant phenotype (Supplemental Table S1). This lack of pharmacological rescue contrasts with the complete amelioration of fasting hepatic steatosis by both a major nutrient and a signaling molecule that coordinates fasting metabolism [Laeger et al. 2010], pharmacologic manipulation of ketone body transport in such states as fasting, uncontrolled type 1 diabetes mellitus, dyslipidemia, and obesity holds therapeutic promise [Veech 2004].

Materials and methods

Fish

The *rmn* 0551 allele is carried on a [Tg(ins:dsRed)m1081]; Tg(fabp10a::dsRed) 045; Tg(gela33:EGFP)m1081 × WIK background. Outcrosses to TL or unrelated AB had no effect on the penetrance or expressivity of the mutant phenotype. These studies were approved by the University of Utah Institutional Animal Care and Use Committee and the Radiation Safety Committee.

ORO staining and screening

Forty to 50 6-dpf animals from individual F2 in-crosses were fixed and stained as described previously [Schlegel and Stainier 2006]. Only fully penetrant (25% of the animals) and fully expressive (unambiguous, uniform increase in liver staining) mutants were analyzed further.

Transgenic rescue constructs

*Tol2* transposase-mediated transgenic expression of wild-type *slc16a6a* cDNA was achieved by placing the *slc16a6a* cDNA under the control of either a 5.3-kb *bactin2* promoter [for broad expression] or a 2.8-kb *fabp10a* promoter [for liver-specific expression] in a *Tol2* transposase destination vector that was co-injected with *Tol2* mRNA into single-cell, fertilized embryos [Her et al. 2003, Kwan et al. 2007]. Parallel constructs driving EGFP under the *bactin2* promoter and mCherry under the *fabp10a* promoter were injected to confirm that broad or liver-limited expression was achieved [respectively] with our experimental design. The human *SLC16A6* cDNA was placed under control of the *fabp10a* promoter.

Electrophysiology

Electrophysiological characterization of Slc16a6a was performed at Ecocyte Biosciences using a Robocyte automated two-elec-
trode voltage clamp recorder (Schnitzler et al. 2003). *Xenopus* oocytes were harvested and injected with either empty pGEMT vector or pGEMT containing *slc16a6a* cDNA preceded by a Kozak translation initiation sequence (5'-GCCACCCACC-3'). The cDNA was cloned in the T7 polymerase reading direction. Four days after injection, oocytes were clamped to a holding potential of ~70 mV, and currents were recorded at a sampling rate of 1000 Hz at room temperature. Substrates (5 mM β-hydroxybutyrate, lactate, or isovalerate) were applied for 10 sec, and the inward current was evaluated.

Metabolite analyses
Following thin-layer chromatographic resolution of individual species, lipids were visualized by placing the silica plates in a sealed chamber containing iodide crystals (Schlegel and Stainier 2006). The resolved lipids were scraped off the plates and analyzed individually. Cholesterol oleate, glycerol triolein, oleic acid, and cholesterol standards were from Sigma. The perchlorate method (Snyder and Stephens 1959) was used for quantifying triacylglycerol exactly as we described previously (Schlegel and Stainier 2006). Cholesterol and cholesteryl esters were quantified using the o-ethylmaleimide method (Rudel and Morris 1973). Free fatty acids were determined using a commercially available (BioVision) essay involving enzymatic activation of coenzyme A derivatives, followed by oxidation in the presence of N-ethylmaleimide (Mizuno et al. 1980). β-Hydroxybutyrate was detected enzymatically [Caymen Chemicals]. Capillary glucose was measured with a Roche glucometer. Serum was diluted in phosphate-buffered saline (PBS) with 1 mM EDTA prior to lipid extraction with a Roche glucometer. Signal was detected with a DIG detection kit (Roche). Immunoblotting
Signal was detected with a DIG detection kit (Roche). Metabolite analyses
Following thin-layer chromatographic resolution of individual species, lipids were visualized by placing the silica plates in a sealed chamber containing iodide crystals (Schlegel and Stainier 2006). The resolved lipids were scraped off the plates and analyzed individually. Cholesterol oleate, glycerol triolein, oleic acid, and cholesterol standards were from Sigma. The perchlorate method (Snyder and Stephens 1959) was used for quantifying triacylglycerol exactly as we described previously (Schlegel and Stainier 2006). Cholesterol and cholesteryl esters were quantified using the o-ethylmaleimide method (Rudel and Morris 1973). Free fatty acids were determined using a commercially available (BioVision) essay involving enzymatic activation of coenzyme A derivatives, followed by oxidation in the presence of N-ethylmaleimide (Mizuno et al. 1980). β-Hydroxybutyrate was detected enzymatically [Caymen Chemicals]. Capillary glucose was measured with a Roche glucometer. Serum was diluted in phosphate-buffered saline (PBS) with 1 mM EDTA prior to lipid extraction with thin-layer chromatographic analysis of triacylglycerol.

Radiotracer study
Larvae (5 dpf) were incubated with 10 mM L-[14C(U)]-leucine tracer for 72 h, and then total lipids were extracted, separated by thin-layer chromatography, and detected by autoradiography using a Molecular Dynamics PhosphorImager. Band intensities (signal) were quantified with GelQuantNET. Band intensities were normalized to the masses of lipid present in the wild-type and *rmn* samples, and a ratio of incorporation relative to mass was calculated as follows: 

\[
\frac{14C \text{signal/mass lipid}_{\text{WT}}}{14C \text{signal/mass lipid}_{\text{rmn}}} = \text{WT:rmn}
\]

Ppara agonist treatment
Forty 5-dpf larvae were treated with clofibrate, fenofibrate, gemfibrozil, or WY 14,643 for 24 h. Animals were then fixed and stained with ORO and scored for the presence of hepatic steatosis.

In situ hybridization
A 461-bp riboprobe was prepared from the 3’ untranslated region (UTR) and final two exons of *slc16a6a* using the following primers to amplify the sequence: forward, 5’-GCAGAGGAGGAAAAA TGGA-3’, and reverse, 5’-GGAAATGGTTAACCCAAA-3’. The product was cloned into pGEMT, and an antisense probe was transcribed using T7 RNA polymerase (Promega) and DIG-labeled nucleotides (Roche). Larvae were digested with proteinase K prior to hybridization exactly as described (Thissen and Thissen 2008). Signal was detected with a DIG detection kit (Roche).

Immunoblotting
Six wild-type and *rmn* mutant livers were sonicated in 300 μL of 50 mM Tris (pH 8.0), 150 mM NaCl, 1.0% IGEPA CA-630, 0.25% sodium deoxycholate, 0.1% SDS, and 1 mM EDTA supplemented with protease and phosphatase inhibitor cocktails (Roche Complete MINI and PhosSTOP). Debris was pelleted by centrifugation. Twenty micrograms of protein (concentration determined with a BCA kit, Thermo) from each lysate was separated by SDS-PAGE, transferred to nitrocellulose membranes, and detected with anti-zebrafish Slc16a6a [21st Century Biochemicals].

Histology
Hematoxylin and eosin sectioning of adult livers was performed by AML Laboratories.

Confocal microscopy
Larvae (6 dpf) were fixed in PBS containing 4% formaldehyde, washed in PBS containing 0.1% saponin (S-PBS), incubated with S-PBS containing BODIPY 493/503 (10 mg/L), washed with S-PBS, and mounted in glycerol after partial dissection of the liver from the body. Confocal images were taken using a Zeiss 510 confocal microscope.

Electron microscopy
Electron microscopy was performed at the University of Utah Electron Microscopy Facility and the J. David Gladstone Institute's Electron Microscopy Core Laboratory. Larvae (6 dpf) were fixed in 2.5% paraformaldehyde and 1% glutaraldehyde in 100 mM sodium cacodylate (pH 7.4), counterstained with OsO4, and sectioned at the level of the liver.

Statistical analysis
The two-sided Student's t-test was used to compare relative gene expression in fasted and fed animals and to compare lipid and protein levels in whole-larval extracts and dissected adult livers. For survival analysis, the log rank test was performed using freeware (http://bioinf.wehi.edu.au/software/russell/logrank).

Other methods are described in Supplemental Material.

Acknowledgments
We thank Carl S. Thummel, Don L. Gibbons, E. Dale Abel, Elizabeth A. Leibold, Jared Rutter, Ivana De Domenico, Jerry Kaplan, Philipp Gut, and David J. Grunwald for comments; Takuya Sakaguchi, Leonard Lipovich, and H. Joseph Yost for advice on positional cloning; Timothy E. Graham for use of his RT–PCR instrument; and Diana Lim for improving Figure 5A. This work was supported by the U.S. National Institutes of Health Grant K08-DK078605, a UCSF Diabetes Education and Research Pilot and Feasibility Award [P30-DK063720], and funds from the University of Utah Molecular Medicine [U2M2] Program to A.S. R.M.A. was supported by a Juvenile Diabetes Research Foundation fellowship. D.Y.R.S. was supported by grants from the U.S. National Institutes of Health [R01-DK060322] and the Packard Foundation.

References
Akimitsu M, Shin-ichi H, Daisuke K, Takenori N, Tomoko I, Davin HES, Satoshi O, Nohuaki O, Kenta H, Sayaka K, et al. 2008. Mutation in the abcb7 gene causes abnormal iron and fatty acid metabolism in developing medaka fish. *Dev Growth Differ* 50: 703–716.
ANDERSON RM, Bosch JA, Goll MG, Hesselson D, Dong PD, Shin D, Chi NC, Shin CH, Schlegel A, Halpern M et al. 2009. Loss of Dnmt1 catalytic activity reveals multiple roles for DNA methylation during pancreas development and regeneration. Dev Biol 334: 213–223.

Babin PJ, Vernier JM. 1989. Plasma lipoproteins in fish. J Lipid Res 30: 467–489.

Bonen A, Heynen M, Hatta H. 2006. Distribution of monocarboxylate transporters MCT1–MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab 31: 31–39.

Boukaftane Y, Duncan A, Wang S, Labuda D, Robert M-E, Sarrazin J, Schappert K, Mitchell GA. 1994. Human mitochondrial HMG CoA synthase: Liver cDNA and partial genomic cloning, chromosome mapping to 1p12-p13, and possible role in vertebrate evolution. Genomics 23: 552–559.

Hugo et al.

Anderson RM, Bosch JA, Goll MG, Hesselson D, Dong PD, Shin D, Chi NC, Shin CH, Schlegel A, Halpern M et al. 2009. Loss of Dnmt1 catalytic activity reveals multiple roles for DNA methylation during pancreas development and regeneration. Dev Biol 334: 213–223.

Babin PJ, Vernier JM. 1989. Plasma lipoproteins in fish. J Lipid Res 30: 467–489.

Bonen A, Heynen M, Hatta H. 2006. Distribution of monocarboxylate transporters MCT1–MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab 31: 31–39.

Boukaftane Y, Duncan A, Wang S, Labuda D, Robert M-E, Sarrazin J, Schappert K, Mitchell GA. 1994. Human mitochondrial HMG CoA synthase: Liver cDNA and partial genomic cloning, chromosome mapping to 1p12-p13, and possible role in vertebrate evolution. Genomics 23: 552–559.

Browning JD, Horton JD. 2004. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147–152.

Cahill GF. 2006. Fuel metabolism in starvation. J Clin Gastroenterol 40: S11–S16. doi: 10.1097/01.mcg.0000168644.23697.31.

Matthews RP, Lorent K, Manoral-Mobias R, Huang Y, Gong W, Murray IVJ, Blair IA, Pack M. 2009. TNFα-dependent hepatic steatosis and liver degeneration caused by mutation of zebrafish s-adenosylhomocysteine hydrolase. Development 136: 865–875.

Mizuno K, Toyosato M, Yabumoto S, Tanimizu I, Hirakawa H. 1980. A new enzymatic method for colorimetric determination of free fatty acids. Anal Biochem 108: 6–10.

Moller L, Stodkilde-Jorgensen H, Jensen FT, Jorgensen JOL. 2008. Fasting in healthy subjects is associated with intraperitoneal uptake of nutrients and associated with intrahepatic accumulation of lipids as assessed by 1H-magnetic resonance spectroscopy. Clin Sci (Lond) 114: 547–552.

Nugent C, Younossi ZM. 2007. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 4: 432–441.

Phillips JW, Bird FJ. 1977. Ketogenesis in vertebrate livers. Comp Biochem Physiol B 57: 133–138.

Pierre K, Pellerin L. 2005. Monocarboxylate transporters in the central nervous system: Distribution, regulation and function. J Neurochem 94: 1–14.

Plata C, Sussman CR, Sindic A, Liang JO, Mount DB, Josephs ZM, Chang M-H, Romero MF. 2007. Zebrafish Slc5a12 encodes an electrophoretic sodium monocarboxylate transporter (SMCTn). J Biol Chem 282: 11996–12009.

Price NT, Jackson VN, Halestrap AP. 1998. Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past. Biochem J 329: 321–328.

Raldúa D, André M, Babin PJ. 2008. Clofibrate and gemfibrozil induce an embryonic malabsorption syndrome in zebrafish. Toxicol Appl Pharmacol 228: 301–314.

Rudel LL, Morris MD. 1973. Determination of cholesterol using o-phthalaldehyde. J Lipid Res 14: 364–366.

Sadler KC, Amsterdam A, Soroka C, Boyer J, Hopkins N. 2005. A genetic screen in zebrafish identifies the mutants vps18, n2 and foie gras as models of liver disease. Development 132: 3561–3572.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, et al. 2010. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675–1685.

Schlegel A, Stainier DY. 2006. Microsomal triglyceride transfer protein is required for yolk lipid utilization and absorption of dietary lipids in zebrafish larvae. Biochemistry 45: 15179–15187.
Schlombs K, Wagner T, Scheel J. 2003. Site-1 protease is required for cartilage development in zebrafish. Proc Natl Acad Sci 100: 14024–14029.

Schnitzler K, Küster M, Methfessel C, Fejtl M. 2003. The robocyte: Automated cDNA/mRNA injection and subsequent TEVC recording on Xenopus oocytes in 96-well microtiter plates. Receptors Channels 9: 41–48.

Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. 2010. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468: 1100–1104.

Snyder F, Stephens N. 1959. A simplified spectrophotometric determination of ester groups in lipids. Biochim Biophys Acta 34: 244–245.

Thakur PC, Stuckenholz C, Rivera MR, Davison JM, Yao JK, Amsterdam A, Sadler KC, Bahary N. 2011. Lack of de novo phosphatidylinositol synthesis leads to endoplasmic reticulum stress and hepatic steatosis in cdip2t-deficient zebrafish. Hepatology 54: 452–462.

Thisse C, Thisse B. 2008. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc 3: 59–69.

Veech RL. 2004. The therapeutic implications of ketone bodies: The effects of ketone bodies in pathological conditions: Ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 70: 309–319.

Walters KB, Dodd ME, Mathias JR, Gallagher AJ, Bennin DA, Rhodes J, Kanki JP, Look AT, Grinblat Y, Huttenlocher A. 2009. Muscle degeneration and leukocyte infiltration caused by mutation of zebrafish fad24. Dev Dyn 238: 86–99.

Wu JW, Wang SP, Alvarez F, Casavant S, Gauthier N, Abed L, Soni KG, Yang G, Mitchell GA. 2011. Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology 54: 122–132.
A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting

Sarah E. Hugo, Lourdes Cruz-Garcia, Santhosh Karanth, et al.

*Genes Dev.* 2012, 26:
Access the most recent version at doi:10.1101/gad.180968.111

---

**Supplemental Material**
http://genesdev.cshlp.org/content/suppl/2012/02/01/26.3.282.DC1

**References**
This article cites 48 articles, 11 of which can be accessed free at:
http://genesdev.cshlp.org/content/26/3/282.full.html#ref-list-1

**License**

**Email Alerting Service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here].

---

**EXIQON**
Boost NGS microRNA profiling. Read about 3 methods tested.

New a QIAGEN company

Copyright © 2012 by Cold Spring Harbor Laboratory Press